EQL Pharma AB (publ) (STO:EQL)

Market Cap	1.64B -24.3%
Revenue (ttm)	425.75M +25.8%
Net Income	29.34M -15.5%
EPS	0.98 -15.6%
Shares Out	29.53M
PE Ratio	56.55
Forward PE	29.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,204
Average Volume	17,015
Open	55.70
Previous Close	55.50
Day's Range	54.30 - 56.30
52-Week Range	46.55 - 98.60
Beta	0.42
RSI	52.78
Earnings Date	May 8, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 55
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In fiscal year 2025, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.